Burden of Illness in Alopecia Areata: A Cross-Sectional Online Survey StudyNatasha Atanaskova Mesinkovska, James V. Cassella, Brett King et al.|Journal of Investigative Dermatology Symposium Proceedings|2020Cited by 105
Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areataBrett King, James V. Cassella, Emma Guttman‐Yassky et al.|Journal of the American Academy of Dermatology|2022Cited by 80
Development of the alopecia areata scale for clinical use: Results of an academic–industry collaborative effortBrett King, Maryanne M. Senna, Natasha Atanaskova Mesinkovska et al.|Journal of the American Academy of Dermatology|2021Cited by 79
Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)Brett King, James V. Cassella, Maryanne M. Senna et al.|Journal of the American Academy of Dermatology|2024Cited by 79